CD7 and acute myeloid leukemia: Therefore, we reclassified AML patients into the DNMT3A-mutated/CD7+ group (n=21) and the other (non-DNMT3Amut/CD7+) group (n=276) based on whether they had concomitant DNMT3A mutation and positive CD7 expression.